<DOC>
	<DOCNO>NCT02223052</DOCNO>
	<brief_summary>This Phase 1 , open-label , multicenter , randomize , 2-stage crossover study consist 2 phase : Stage I - Pharmacokinetics ( Bioequivalence ) , Extension Stage II - Pharmacokinetics ( Food Effect ) Extension This study enroll approximately 60 subject stage I 60 subject stage II hematologic solid tumor malignancy , exclude gastrointestinal tumor tumor originate metastasize liver standard treatment exists progress recur follow prior therapy . Subjects must eligible therapy higher curative potential alternative treatment show prolong survival analogous population . Approximately 23 site US 2 Canada participate study .</brief_summary>
	<brief_title>Bioequivalence &amp; Food Effect Study Patients With Solid Tumor Hematologic Malignancies</brief_title>
	<detailed_description>Stage I - Pharmacokinetics ( Bioequivalence ) Subjects randomized receive CC-486 300 mg orally two pharmacokinetic ( PK ) study day base dose sequence randomize : Dosing Sequence 1 : 2x150 mg tablet follow 1x30 mg tablet . Dosing Sequence 2 : 1x300 mg tablet follow 2x150 mg tablet . Each dose administer clinic least 48 hour apart PK dose day 1 PK dose day 2 period longer 10 day fast condition . Stage II - Pharmacokinetics ( Food Effect ) Subjects randomized receive CC-486 300 mg orally two PK study day base dose sequence randomize : Dosing Sequence 1 : 1x300 mg tablet fast condition follow 1x300 mg tablet feed condition . Dosing Sequence 2 : 1x300 mg tablet feed condition follow 1x300 mg tablet fast condition . Each dose administer clinic least 48 hour apart PK dose day 1 PK dose day 2 period longer 10 day . The sponsor generate randomization scheme assign subject upon enrollment appropriate sequence dosing : Fasted condition : follow overnight fast least 10 hour , subject ingest oral Azacitidine 240 mL room temperature water . Subjects must fast minimum 4 hour follow oral Azacitidine administration . Subjects may drink water desire , except 1 hour 1 hour oral Azacitidine administration . Fed condition : follow overnight fast least 10 hour follow performance require pre-dose assessment , subject randomize receive test medication feed state begin ingest breakfast meal 30 ( ±5 ) minute prior plan administration oral Azacitidine . They continue entire meal within 20 25 minute ( less 20 minute ) time meal serve . Subjects ingest oral Azacitidine 240 mL room temperature water . Subjects must fast minimum 4 hour follow oral Azacitidine administration . Subjects may drink water desire , except 1 hour 1 hour administration oral Azacitidine . Extension Phase ( subject complete PK Stage I Stage II ) Subjects continue beyond pharmacokinetics phase ( Stage I Stage II ) enter extension phase study discretion investigator receive &lt; 6 ( four-week ) cycle Vidaza 75 mg/m2 IV SC daily 7 day clinic repeat every 4 week per prescribe label discretion investigator ≤ 6 ( four-week ) cycle .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Thyroid Neoplasms</mesh_term>
	<mesh_term>Osteosarcoma</mesh_term>
	<mesh_term>Hematologic Neoplasms</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>Subjects must satisfy follow criterion enrol study : 1 . Age ≥ 18 year age time sign informed consent document . 2 . Understand voluntarily sign informed consent document prior study related assessments/procedures conduct . 3 . Documented diagnosis follow : 1 . Myelodysplastic Syndrome ( MDS ) accord World Health Organization ( WHO ) 2008 classification 2 . Acute myeloid leukemia ( AML ) 3 . Multiple myeloma ( MM ) , limited patient standard curative palliative treatment exist longer effective 4 . NonHodgkin 's lymphoma ( NHL ) , limited patient standard curative palliative treatment exist longer effective , 5 . Hodgkin 's lymphoma ( HL ) , limited patient standard curative palliative treatment exist longer effective 6 . Metastatic inoperable solid tumors* ( except gastrointestinal tumor tumor originate metastasized liver ) standard treatment exists , progress recur follow prior therapy . Subjects must eligible therapy higher curative potential alternative treatment show prolong survival analogous population . 4 . Patients history treat brain metastasis clinically stable ≥ 4 week prior sign inform consent . Glucocorticoid therapy central nervous system ( CNS ) edema permit ≤ 20 mg prednisolone ( equivalent ) . 5 . Have Eastern Cooperative Oncology Group ( ECOG ) performance status 02 . 6 . Have life expectancy ≥ 3 month . 7 . Have stable renal function without dialysis least 2 month prior Investigational Product ( IP ) administration define : 1 . Serum creatinine &lt; 2.5 x upper limit normal ( ULN ) 2 . An average calculated creatinine clearance &gt; 30 mL/min/1.73 m^2 8 . Have organ marrow function screen predose visit define : 1 . Hemoglobin ≥ 8 g/dL 2 . Absolute neutrophil count ( ANC ) ≥ 0.75 x 10^3/uL without treatment myeloid growth factor within 3 day prior first dose IP 3 . Platelets ≥ 30 x 10^3/uL 4 . Total bilirubin ≤ 1.5 x Upper Limits Normal ( ULN ) 5 . Aspartate aminotransferase ( AST ) ≤ 2 x ULN 6 . Alanine aminotransferase ( ALT ) ≤ 2 x ULN 9 . Have 12lead Electrocardiogram ( ECG ) clinically significant screening , determine investigator 10 . Females childbearing potential ( FCBP ) may participate , provide subject meet follow condition : Agree use least two effective contraceptive method ( oral , injectable , implantable hormonal contraceptive ; tubal ligation ; intrauterine device ; barrier contraceptive spermicide ; vasectomized partner ) agree practice true abstinence throughout study , 3 month follow last dose IP ; Negative serum pregnancy test screening ( sensitivity least 25 mIU/mL ) ; ( Note screen serum pregnancy test use test prior start IP pharmacokinetics phase perform within 72hour timeframe ) , Negative serum urine pregnancy test ( investigator 's discretion ; sensitivity least 25 mIU/mL ) within 72 hour prior start IP extension phase . ( Note : subject must negative serum urine pregnancy test prior dose Day 1 treatment cycle extension phase . ) 11 . Male subject must : . Practice true abstinence* agree use least two physicianapproved contraceptive method throughout course study avoid father child course study least 3 month follow last dose IP . * True abstinence acceptable line prefer usual lifestyle patient . [ Periodic abstinence ( e.g. , calendar , ovulation , symptothermal , postovulation method ) withdrawal acceptable method contraception ] . 12 . Able adhere study visit schedule protocol requirement . 1 . Women pregnant nursing ( lactate ) . 2 . Gastrointestinal tumor , tumor originate metastasized liver , tumor know interfere absorption , distribution , metabolism , excretion drug . 3 . Had chemotherapy radiotherapy within 4 week prior first day Investigational Product ( IP ) administration . 4 . Have treat investigational agent within 4 week prior first day IP administration . 5 . Have ongoing clinically significant adverse event ( ) due prior treatment administer determined investigator . 6 . Significant active cardiac disease within previous 6 month , include : New York Heart Association ( NYHA ) class IV congestive heart failure Significant cardiac arrhythmia unstable angina angina require surgical medical intervention ; and/or Myocardial infarction 7 . Have know suspected hypersensitivity azacitidine ingredient use manufacturing Azacitidine . 8 . Uncontrolled systemic fungal , bacterial , viral infection ( define ongoing signs/symptoms related infection without improvement despite appropriate antibiotic , antiviral therapy , and/or treatment ) 9 . History inflammatory bowel disease ( e.g . Crohn 's disease , ulcerative colitis ) , celiac disease , prior gastrectomy , gastric bypass , upper bowel removal , gastrointestinal disorder defect would interfere absorption study drug and/or predispose subject increase risk gastrointestinal toxicity . 10 . Any significant medical condition , laboratory abnormality , psychiatric illness would prevent subject participate study . 11 . Any condition include presence laboratory abnormality , place subject unacceptable risk he/she participate study 12 . Any condition confound ability interpret data study 13 . Impaired ability swallow oral medication 14 . Any condition confound ability interpret data study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>CC-486</keyword>
	<keyword>Oral Azacitidine</keyword>
	<keyword>Soli Tumor Malignancy</keyword>
	<keyword>Hematological Malignancy</keyword>
	<keyword>Leukemia</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>Multiple Myeloma</keyword>
	<keyword>Acute Myeloid Leukemia</keyword>
	<keyword>Myelodysplastic Syndromes</keyword>
	<keyword>Neoplasms</keyword>
	<keyword>Melanoma</keyword>
	<keyword>Breast Cancer</keyword>
	<keyword>Metastatic Breast Cancer</keyword>
	<keyword>Non-Small Cell Lung Cancer</keyword>
	<keyword>Small Cell Lung Cancer</keyword>
	<keyword>Renal Cell Carcinoma</keyword>
	<keyword>Glioblastoma Multiforme</keyword>
	<keyword>Brain Cancer</keyword>
	<keyword>Kidney Cancer</keyword>
	<keyword>Lung cancer</keyword>
	<keyword>Blood Cancer</keyword>
	<keyword>Thyroid Cancer</keyword>
	<keyword>Bone Cancer</keyword>
	<keyword>Bone Metastasis</keyword>
	<keyword>Testicular Cancer</keyword>
	<keyword>Prostate Cancer</keyword>
	<keyword>Bladder Cancer</keyword>
	<keyword>Ovarian Cancer</keyword>
	<keyword>Skin Cancer</keyword>
	<keyword>Cancer general</keyword>
	<keyword>Survival</keyword>
	<keyword>Chemotherapy</keyword>
	<keyword>Targeted Therapy</keyword>
	<keyword>Genitourinary</keyword>
	<keyword>MM</keyword>
	<keyword>MDS</keyword>
	<keyword>AML</keyword>
	<keyword>NHL</keyword>
	<keyword>HL</keyword>
	<keyword>MBC</keyword>
	<keyword>NSCLC</keyword>
	<keyword>SCLC</keyword>
	<keyword>GBM</keyword>
</DOC>